Who is sponsoring NCT05195840?

NCT05195840 is sponsored by University of Louisville.

What drugs are being tested in NCT05195840?

Interventions in NCT05195840: Personalized Treatment for Eating Disorders, Cognitive Behavioral Therapy for Eating Disorders.

What condition does NCT05195840 study?

NCT05195840 studies Eating Disorders.

Is NCT05195840 still recruiting?

NCT05195840 is currently completed. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT05195840: PT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized Treatment for Eating Disorders Versus CBT-E Trial

Completed NA Last updated 24 March 2026

What this trial tests

NA trial testing Personalized Treatment for Eating Disorders in Eating Disorders in 80 participants. Completed in 29 January 2026.

Timeline

6 April 2022

Primary endpoint
30 November 2025

29 January 2026

Quick facts

Lead sponsor	University of Louisville
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	6 April 2022
Primary completion	30 November 2025
Estimated completion	29 January 2026
Sites	1 location across United States

Drugs / interventions tested

Personalized Treatment for Eating Disorders
Cognitive Behavioral Therapy for Eating Disorders

Conditions studied

Eating Disorders — all drugs for Eating Disorders →

Sponsor

University of Louisville

Who can join

Adults 18 to 65, any sex, with Eating Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The scientific premise, developed from past work, is that treatment personalized based on idiographic models (termed Network Informed Personalized Treatment; NA-PT) will outperform the current gold-standard treatment (Enhanced Cognitive Behavioral Therapy: CBT-E). The study goals are to (1) develop and test the acceptability, feasibility, and preliminary efficacy of a randomization of NA-PT versus CBT-E and (2) to test if network-identified precision targets are the mechanism of change. These goals will ultimately lead to the very first personalized treatment for ED and can be extended to additional psychiatric illnesses. Specific aims are (1) To collect preliminary data on the feasibility and acceptability of the randomization of NA-PT (n=40) for EDs versus CBT-E (n=40), (2) To test the initial clinical efficacy of NA-PT versus CBT-E on clinical outcomes (e.g., ED symptoms, body mass index, quality of life) and (3) To examine if changes in NA-identified, precision targets, as well as in dynamic network structure, are associated with change in clinical outcomes.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A pilot randomized controlled trial of transdiagnostic network-informed personalized treatment for eating disorders versus enhanced cognitive behavioral therapy.
Butler RM, Ortiz AML, Pennesi JL, Crumby EK, et al · · 2023 · cited 8× · PMID 37572006 · DOI 10.1002/eat.23982
Preliminary Investigation of a Focused Regular Eating Intervention to Address Problematic Restriction in the Context of Evidence-Based Personalized Treatment.
Harris LM, Vanzhula IA, Hooper S, Levinson CA. · · 2026 · PMID 41250820 · DOI 10.1002/eat.24600

Verify or expand the search:

Other recruiting trials for Eating Disorders

Currently open trials in the same condition.

NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
NCT07295197 — Oral Indicators for ED Screening · recruiting
NCT07082777 — Recovery in Telling Life Stories · NA · recruiting
NCT07042672 — Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity · recruiting
NCT07017322 — Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders · NA · recruiting

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05195840 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05195840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing